Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (81-90 of 198) with videos related to

Pageof 20
Sort By:
Arthritis Research & Therapy|December 23, 2011
Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohortMandana Nikpour, Pravin Hissaria, Jillian Byron, et al.
BMC Urology|September 3, 2022
Differentiation of renal masses with multi-parametric MRI: the de Silva St George classification schemeSuresh de Silva, Kathleen R Lockhart, Peter Aslan, et al.
Rheumatology and Therapy|April 8, 2026
Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
Rheumatology and Therapy|May 23, 2022
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 TrialsPhilip Mease, Arthur Kavanaugh, Dafna Gladman, et al.
Rheumatology and Therapy|September 18, 2021
Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled TrialsPhilip J Mease, Dafna D Gladman, Arthur Kavanaugh, et al.
Arthritis Care & Research|August 30, 2018
Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical TrialsPhilip Mease, Euthalia Roussou, Gerd-Rüdiger Burmester, et al.
International Journal of Rheumatic Diseases|January 20, 2021
A patient-centered knowledge translation tool for treat-to-target strategy in rheumatoid arthritis: Patient and rheumatologist perspectivesHelen Benham, Hedva Chiu, Joanne Tesiram, et al.
European Journal of Rheumatology|November 3, 2018
Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparisonWalter P Maksymowych, Vibeke Strand, Peter Nash, et al.
The Journal of Rheumatology|July 9, 2008
Drug use and toxicity in psoriatic disease: focus on methotrexateWilliam J Taylor, Eleanor Korendowych, Peter Nash, et al.
Rheumatology and Therapy|September 7, 2022
Correction: Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower RegistryAlexis Ogdie, Kelley Myers, Carol Mansfield, et al.
Pageof 20

Showing results (81-90 of 198) with videos related to

Sort By:
Pageof 20
Arthritis Research & Therapy|December 23, 2011
Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohortMandana Nikpour, Pravin Hissaria, Jillian Byron, et al.
BMC Urology|September 3, 2022
Differentiation of renal masses with multi-parametric MRI: the de Silva St George classification schemeSuresh de Silva, Kathleen R Lockhart, Peter Aslan, et al.
Rheumatology and Therapy|April 8, 2026
Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
Rheumatology and Therapy|May 23, 2022
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 TrialsPhilip Mease, Arthur Kavanaugh, Dafna Gladman, et al.
Rheumatology and Therapy|September 18, 2021
Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled TrialsPhilip J Mease, Dafna D Gladman, Arthur Kavanaugh, et al.
Arthritis Care & Research|August 30, 2018
Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical TrialsPhilip Mease, Euthalia Roussou, Gerd-Rüdiger Burmester, et al.
International Journal of Rheumatic Diseases|January 20, 2021
A patient-centered knowledge translation tool for treat-to-target strategy in rheumatoid arthritis: Patient and rheumatologist perspectivesHelen Benham, Hedva Chiu, Joanne Tesiram, et al.
European Journal of Rheumatology|November 3, 2018
Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparisonWalter P Maksymowych, Vibeke Strand, Peter Nash, et al.
The Journal of Rheumatology|July 9, 2008
Drug use and toxicity in psoriatic disease: focus on methotrexateWilliam J Taylor, Eleanor Korendowych, Peter Nash, et al.
Rheumatology and Therapy|September 7, 2022
Correction: Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower RegistryAlexis Ogdie, Kelley Myers, Carol Mansfield, et al.
Pageof 20